EKF Diagnostics Launches POC Hemoglobin Analyzer At Medica 2014

Cardiff, UK - EKF Diagnostics, the global diagnostics company, has introduced the DiaSpect TM point of care (POC) hemoglobin analyzer at Medica 2014, 12-15^th November, Düsseldorf, Germany. Alongside this new product, EKF exhibited a new version of its Hemo Control hemoglobin analyzer, the industry-leading Biosen glucose and lactate analyzer, as well as previewing SensPoint, a new lactate analyzer designed for use in professional medical settings.  

Immediate hemoglobin results

The new DiaSpect Tm hemoglobin analyzer is a palm-sized point of care analyzer that is fast, easy to use and reliable in all climate conditions as it combines laboratory quality performance with unmatched measurement speed and extensive battery life. 

In addition to its accuracy of result, DiaSpect Tm is extremely robust since it has no moving parts. Furthermore it utilizes reagent-free microcuvettes which are unaffected by humidity, unlike reagent-based systems. These plexiglass microcuvettes also have a long shelf-life of 2.5 years with no need for refrigeration as they can be stored from 0° to 50°C. DiaSpect Tm is portable and lightweight at just 185g and has an extremely long battery life of 40 days of continuous use, or 10,000 tests, due to its integrated rechargeable lithium-ion battery.

DiaSpect Tm is factory calibrated against the HiCN reference method in accordance with ICSH and requires no re-calibration or maintenance, as it undertakes an automatic self-check between every measurement. Its ‘always on’ technology also means the analyzer is permanently ready for use.

The user simply collects a capillary or venous blood sample of <10 µL in the microcuvette and inserts it directly into the analyzer. Hemoglobin results are delivered in just one second which can then be downloaded to a PC via USB or Bluetooth.

About EKF Diagnostics

EKF Diagnostics Holdings plc, which includes the EKF Diagnostics, EKF Molecular, Stanbio Laboratory, Separation Technology Inc, DiaSpect and Selah Genomics brands, specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new molecular division, EKF Molecular Diagnostics, focuses on technology used within the development of companion diagnostics, specifically within oncology.  EKF products are sold in more than 100 countries around the globe, through a network of specialist distributors.

Point-of-care diagnostics: EKF Diagnostics designs and manufactures world-class diagnostic devices, as well as distributing rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.

Central laboratory: EKF, through its wholly owned subsidiary, Stanbio Laboratory (Boerne, Texas, USA), manufactures a comprehensive range of clinical chemistry reagents. In addition, EKF Life Sciences (Elkhart, Indiana, USA) manufactures enzymes used in reagent development and also provides contract fermentation facilities.

Molecular Diagnostics: In March 2013 EKF set up a new division to focus on molecular and companion diagnostics following the acquisition of UK-based 360 Genomics. EKF Molecular Diagnostics’ technology, PointMan™, is capable of detecting mutant genes from tiny biopsy and blood samples and has recently entered a partnership with the world renowned cancer research center at Massachusetts General Hospital, USA.

EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.